The increasing use of immunotherapies in cancer will lead to more cases of steroid-refractory colitis that can only be treated with infliximab, gastroenterologists predict. But the anti-TNF drug is not available on the PBS or hospital formularies for the treatment immunotherapy-related colitis, and so patients may be denied access to effective treatment for the serious, ...
Medicines
Increase in immunotherapy colitis highlights need for infliximab
By Michael Woodhead
23 Jun 2020